Compare
Lilly (Eli) vs Pfizer (LLY vs PFE)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Lilly (Eli) (LLY) returned +46.2% and Pfizer (PFE) +19.4%; so far this year the figures are +26.0% and +18.0%.
Lilly (Eli) is the larger company by market value, about 7.6 times the size of Pfizer.
On trailing earnings, LLY trades at 43.9 times and PFE at 42.0 times.
Revenue grew +45.5% at LLY and +1.3% at PFE over the last year.
LLY yields 0.49%. PFE yields 5.85%.
Data as of the latest close. Not investment advice.
Relative performance
| LLY | PFE | |
|---|---|---|
| Price | $1,354.00 | $29.39 |
| 1-day | -0.79% | -1.64% |
| YTD | +25.99% | +18.03% |
| 1 year | +46.25% | +19.42% |
| 3 years | +144.20% | -3.67% |
| Market cap | $1.27T | $167.5B |
| P/E | 43.9 | 42.0 |
| P/S | 14.73 | 2.63 |
| P/B | 31.63 | 1.88 |
| Revenue growth | +45.50% | +1.30% |
| EPS growth | +50.70% | -59.30% |
| Gross margin % | 83.6 | 73.4 |
| Net margin % | 31.9 | 6.3 |
| ROE % | 68.5 | 4.5 |
| Debt / equity | 1.23 | 0.70 |
| FCF yield % | 2.4 | 7.0 |
| Dividend yield % | 0.49 | 5.85 |
| Beta | 0.29 | 0.26 |
| RSI (14) | 61.1 | 49.5 |
| Technical rating |